semaglutide and cardiovascular disease outcomes of tirzepatide for patients with type 2 diabetes in clinical practice International Clinical Trial Finds that

doi: 10.1002/fsn3.1818 176

Semaglutide 2.4 mg (Wegovy) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity and starting body mass index (BMI)

Individual results vary based on dosage, adherence to nutrition and exercise protocols, and starting weight

And retatrutide vs tirzepatide comparisons suggest retatrutide edges ahead by 3 to 5 percentage points at comparable dose levels